Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037974 | 0.84 | LMNA (0.59) | LMNAHPGDKMT2AALDH1A1GAA | |
| SCHEMBL5276141 | 0.82 | FFAR1 (0.52) | LMNAMEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL6037885 | 0.81 | LMNA (0.55) | LMNAHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL15437144 | 0.79 | MEN1 (0.65) | LMNAHPGDMEN1KMT2AMAPK1 | |
| SCHEMBL12294453 | 0.79 | MEN1 (0.65) | LMNAHPGDMEN1KMT2AMAPK1 | |
| SCHEMBL6038200 | 0.79 | CA1 (0.71) | LMNAMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5281557 | 0.78 | LMNA (0.50) | LMNAHPGDKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5325209 | 0.78 | LMNA (0.51) | LMNAHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL5282172 | 0.77 | LMNA (0.49) | LMNAHPGDKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL11253516 | 0.77 | MEN1 (0.63) | LMNAMEN1KMT2AMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | disclosed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | LMNA 851/4885HPGD 2248/4885MEN1 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.